The Patent Finder

Alkermes Controlled Therapeutics, II

Also on record
Records under this name other than patents Alkermes Controlled Therapeutics, II holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Alkermes Controlled Therapeutics, II

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,919,499Naltrexone Long Acting Formulations and Methods of Use
Formerly held
In force
 · High confidence
In forceHigh confidence
US 7,279,579Polymorphic Forms of Naltrexone
Formerly held
Term ended
Term ended May 7, 2026 · High confidence
Term endedTerm ended May 7, 2026High confidence
US 8,389,540Polymorphic Forms of Naltrexone
Formerly held
Lapsed on the fee record
Ended Mar 5, 2025 · High confidence
Lapsed on the fee recordEnded Mar 5, 2025High confidence
US 6,987,111Aripiprazole, Olanzapine and Haloperidol Pamoate Salts
Formerly held
Term ended
Term ended May 10, 2024 · High confidence
Term endedTerm ended May 10, 2024High confidence
US 8,759,351Methods for Administering Aripiprazole
Formerly held
Term ended
Ended no later than Aug 6, 2023 · Low confidence
Term endedEnded no later than Aug 6, 2023Low confidence
US 6,331,317Apparatus and method for preparing microparticles
Term ended
Term ended Nov 12, 2019 · USPTO record
Term endedTerm ended Nov 12, 2019USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited